1. Show article details.

    Spectrum Pharmaceuticals Announces Second Quarter 2015 Financial Results Teleconference and Webcast

    Business Wire – 7:00 AM ET 07/30/2015

    Spectrum Pharmaceuticals (SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced it will host a teleconference and webcast with management to discuss the second quarter 2015 financial results, provide an update on the Company's business, and discuss expectations for the future.

  2. Show article details.

    Rodman & Renshaw 2015 Annual Global Investment Conference to be held in New York from September 8 to 10, 2015

    PR Newswire – 10:00 AM ET 07/09/2015

    NEW YORK, July 9, 2015 Rodman & Renshaw Conferences, LLC is hosting The Rodman & Renshaw Annual Global Investment Conference on September 8 through September 10, 2015 at the St. Regis Hotel in New York.  More than 200 public & private companies from around the world are expected to present to an audience of over 2,000 attendees.

  3. Show article details.

    Spectrum Pharmaceuticals Announces Publication of Beleodaq® Data Selected as a Rapid Communication in the Journal of Clinical Oncology

    Business Wire – 7:00 AM ET 06/24/2015

    Spectrum Pharmaceuticals (SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, announced today the publication of results from the pivotal BELIEF Study, which was selected as a Rapid Communication in the Journal of Clinical Oncology, the journal of the American Society of Clinical Oncology.

  4. Show article details.

    Wall Street expects these health-care stocks to rise up to 55%

    MarketWatch – 2:20 PM ET 05/29/2015

    The sector's long-term track record of outperformance is likely to continue, analysts say. There's still value to be found in the stock market's best-performing sector, according to Wall Street analysts, despite the seemingly endless flow of articles saying equities are too expensive. It's easy to predict a "correction," which is typically defined as a broad stock market decline of 10% to 20%.

  5. Show article details.

    Spectrum Pharmaceuticals Highlights Five Abstracts of Clinical Data at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois, May 29-June 2, 2015

    Business Wire – 7:00 AM ET 05/29/2015

    Spectrum Pharmaceuticals, Inc. (SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced presentations of clinical data for Beleodaq®, Folotyn® and Poziotinib to be presented at the American Society of Clinical Oncology Annual Meeting, being held in Chicago, Illinois, from May 29 to June 2, 2015.

  6. Show article details.

    Spectrum Pharmaceuticals to Present Corporate Update at the Jefferies Global Healthcare Conference in New York City on June 3rd

    Business Wire – 7:00 AM ET 05/28/2015

    Spectrum Pharmaceuticals, Inc. (SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced that an overview of the Company's business strategy and commercial and development-stage programs will be given at the Jefferies Global Healthcare Conference being held at the Grand Hyatt in New York City.

  7. Show article details.

    Spectrum Pharmaceuticals Commits to Review Shareholder Proposal

    Business Wire – 7:00 AM ET 05/14/2015

    Spectrum Pharmaceuticals, Inc. (SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today commented on the recent filing by Armistice Capital LLC, asking the Spectrum Board of Directors to consider certain actions.

  8. Show article details.

    Wall Street's favorite stocks fly below the radar

    MarketWatch – 10:26 AM ET 05/12/2015

    Among the top 10 companies, potential one-year gains range from 42% to 73%. What do you think of the daily warnings that the stock market is overvalued? Some of the town criers hang their hats on valuation.

Page:

Today's and Upcoming Events

  • Aug
    6

    SPPI to announce Q2 earnings After Market (Confirmed)

  • Aug
    6

    SPPI Earnings Conference Call at 4:30 PM Listen

Past Events (last 90 days)

No events in the past 90 days

Data provided by Wall Street Horizon, Inc. © 2015

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.